Zepbound News

Novo Undercuts Lilly With High-Dose Wegovy at $399 a Month - Bloomberg.com

Novo Undercuts Lilly With High-Dose Wegovy at $399 a Month Bloomberg.com

She Lost 100 Pounds on Zepbound. Then Her Insurance Cut Her Off - Business Insider

She Lost 100 Pounds on Zepbound. Then Her Insurance Cut Her Off Business Insider

Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen - Eli Lilly

Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen Eli Lilly

FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market - CNBC

FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market CNBC

US weight-loss drugmakers slash prices in fight to win customers - BBC

US weight-loss drugmakers slash prices in fight to win customers BBC

Kroger Brings Zepbound® KwikPen to Retail Pharmacy, Expanding Access and Savings for Self-Pay Patients - Kroger

Kroger Brings Zepbound® KwikPen to Retail Pharmacy, Expanding Access and Savings for Self-Pay Patients Kroger

Pricing and availability of Novo, Lilly's weight-loss drugs - Reuters

Pricing and availability of Novo, Lilly's weight-loss drugs Reuters

Lilly's obesity pill Foundayo gains early blockbuster forecast as analysts float 5M+ prescriptions in 2026 - Fierce Pharma

Lilly's obesity pill Foundayo gains early blockbuster forecast as analysts float 5M+ prescriptions in 2026 Fierce Pharma

Multi-Dose KwikPen Now Available for Zepbound Administration - Gastroenterology Advisor

Multi-Dose KwikPen Now Available for Zepbound Administration Gastroenterology Advisor

Zepbound vs. Wegovy: Which Weight Loss Medication Is Better Right Now? - Parade

Zepbound vs. Wegovy: Which Weight Loss Medication Is Better Right Now? Parade

Publix Pharmacy provides access to savings on GLP-1 Zepbound multi-dose KwikPen - Publix

Publix Pharmacy provides access to savings on GLP-1 Zepbound multi-dose KwikPen Publix

Foundayo vs Zepbound: How Eli Lilly’s new weight loss pill compares to its injectable - The Independent

Foundayo vs Zepbound: How Eli Lilly’s new weight loss pill compares to its injectable The Independent

A New Form of GLP-1s Could Revolutionize Weight-Loss Treatment (Again)—And It's Available Now - Oprah Daily

A New Form of GLP-1s Could Revolutionize Weight-Loss Treatment (Again)—And It's Available Now Oprah Daily

A new weight-loss pill is here. Here's how Foundayo compares to Wegovy, Zepbound, and other GLP-1 rivals. - Business Insider

A new weight-loss pill is here. Here's how Foundayo compares to Wegovy, Zepbound, and other GLP-1 rivals. Business Insider

Media Statement: Zepbound (tirzepatide) KwikPen now available at self-pay pricing at major pharmacies nationwide in addition to LillyDirect - Eli Lilly

Media Statement: Zepbound (tirzepatide) KwikPen now available at self-pay pricing at major pharmacies nationwide in addition to LillyDirect Eli Lilly

Zepbound Blindness Lawsuit [2026 Update] - robertkinglawfirm.com

Zepbound Blindness Lawsuit [2026 Update] robertkinglawfirm.com

Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen - CNBC

Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen CNBC

Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight - Eli Lilly

Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight Eli Lilly

Eli Lilly Launches Zepbound KwikPen Multi-Dose Tirzepatide Pen for Adults With Obesity - HCPLive

Eli Lilly Launches Zepbound KwikPen Multi-Dose Tirzepatide Pen for Adults With Obesity HCPLive

Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site - CNBC

Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site CNBC

Lilly courts employers in new push to broaden Zepbound access - FirstWord Pharma

Lilly courts employers in new push to broaden Zepbound access FirstWord Pharma

Human Resources — Benefits shares four updates about prescription plan - Purdue University

Human Resources — Benefits shares four updates about prescription plan Purdue University

The next wave of GLP-1 drugs are coming—and they’re stronger than Wegovy and Zepbound - Scientific American

The next wave of GLP-1 drugs are coming—and they’re stronger than Wegovy and Zepbound Scientific American

Eli Lilly Recall Push On Compounded Zepbound And Investor Risk Questions - Yahoo Finance

Eli Lilly Recall Push On Compounded Zepbound And Investor Risk Questions Yahoo Finance

White House strikes deals for lower prices on obesity drugs - NPR

White House strikes deals for lower prices on obesity drugs NPR

Zepbound vs. Wegovy: Which Weight Loss Treatment Comes Out on Top? - Everyday Health

Zepbound vs. Wegovy: Which Weight Loss Treatment Comes Out on Top? Everyday Health

Queer Eye's Tan France helps unthread obesity bias as part of Zepbound's (tirzepatide) 'Changing the Thread Collection' - Eli Lilly

Queer Eye's Tan France helps unthread obesity bias as part of Zepbound's (tirzepatide) 'Changing the Thread Collection' Eli Lilly

When Weight-Loss Drugs Don’t Work - The New York Times

When Weight-Loss Drugs Don’t Work The New York Times

Race to launch weight-loss pill heats up as Lilly wins US approval - Reuters

Race to launch weight-loss pill heats up as Lilly wins US approval Reuters

Lilly's Zepbound and Taltz improve psoriasis symptoms, drive weight loss in study - CNBC

Lilly's Zepbound and Taltz improve psoriasis symptoms, drive weight loss in study CNBC

Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight | Eli Lilly and Company - Eli Lilly

Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight | Eli Lilly and Company Eli Lilly

Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans - Eli Lilly

Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans Eli Lilly

Obesity Deep Dive: The Unparalleled Launch Success of Mounjaro and Zepbound - IQVIA

Obesity Deep Dive: The Unparalleled Launch Success of Mounjaro and Zepbound IQVIA

Eli Lilly, Walmart to offer first retail pickup option for discounted vials of weight loss drug Zepbound - CNBC

Eli Lilly, Walmart to offer first retail pickup option for discounted vials of weight loss drug Zepbound CNBC

Eli Lilly launches program for employers to subsidize cost of obesity drug outside insurance - statnews.com

Eli Lilly launches program for employers to subsidize cost of obesity drug outside insurance statnews.com

Novo Nordisk’s next-gen obesity drug stumbles in comparison study - statnews.com

Novo Nordisk’s next-gen obesity drug stumbles in comparison study statnews.com

Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions | Eli Lilly and Company - Eli Lilly

Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions | Eli Lilly and Company Eli Lilly